Alligator Bioscience discovers and develops innovative protein based drug candidates for inflammation and cancer diseases with high unmet medical needs. Drug discovery and development at Alligator Bioscience spans early research phases with lead identification up to proof of concept phase I/II studies in patients.

In the discovery of novel protein-based drugs, Alligator Bioscience has a particular asset in it’s proprietary protein optimization technology FIND® (Fragment INduced Diversity). By the use of FIND® , virtually any characteristic of an antibody or a protein can be optimized, translating into significant clinical benefits. These include higher efficacy and potency, as well as improved safety profile, with the aim to increase the probability of successful development and commercialization of biopharmaceuticals.

Alligator Bioscience AB was founded in 2001 and is a privately held company located in Lund, Sweden.